Food and Drug Administration (FDA) Commissioner Scott Gottlieb offers a new pathway for the complete approval and acceptance of hemp-derived cannabidiol, popularly known as CBD as a food additive and supplement. He addressed a Congressional committee saying that he has heard the people’s voice:
“We heard Congress loud and clear…Congress wants there to be a pathway for CBD to be available. We’re deeply focused on this. We have taken on other hard challenges before..”
Gottlieb told the House Appropriations Committee on Wednesday, “You have my commitment I’m focused on this one.”
Commissioner Gottlieb followed this up with a pledge that the FDA will hold a public meeting in the next month, April to initiate a rulemaking procedure for the rightful use of CBD. Gottlieb says that his ultimate goal is to create “an appropriately efficient and predictable regulatory framework for regulating CBD products.”
He floated what a possible framework might look like. He suggested that high concentrations of CBD would be labelled as a drug and will come under stringent oversight, contrarily for lower concentrations, CBD could be used as an additive for various edibles including food products and beverages with an easier review process.
“There is not a good proxy for us doing this through regulation, and if we get comments back and find this is sufficiently complicated for the agency, we will come back and have a conversation with Congress on with how we might be able to work together on this,” Gottlieb said.
Congress’ legalization of hemp derived CBD is supposed to pave new ways for a booming industry that could capture the consumer market and steer it with possible health benefits improving ways of medical treatment for patients.
Although some companies technically restrict the use of cannabis it food, dietary supplements and drinks, there are ample of others who are anyway freely creating cannabis-infused products.
According to Gottlieb, the significant health benefits of CBD with a therapeutic nature and a regulatory process for pharmaceutical-grade CBD will give researchers and drug makers more incentive to research and develop CBD-derived drugs.
He said, “As such, for CBD to be legally marketed as an ingredient in a food or dietary supplement, the law requires that the FDA first would need to issue a regulation to permit such marketing.”
CBD-Infused Products Flood in the Market
Products containing CBD have been continually flooding the market in the past few years, first the government was concerned about the possible ill-effects, however, that has taken a turn to looking at the therapeutic effects of CBD and its potential health benefits.
CBD is one of the major components of the cannabis plant. It is non-psychoactive in nature and does not cause any “high”. Another component, tetrahydro cannabinoid (THC) is psychoactive and can possibly cause mental disorders or aggravate symptoms of stress, depression, anxiety, insomnia and many other, which is why it is prohibited for consumer use.
The new legislation about cannabis legalization has piqued the interest of an array of multi-national companies that are reportedly creating cannabis infused new products including food items, supplements, beverages, candies like jelly beans and even beauty products.
US Department Of Agriculture Releases it’s Guide to Legal Use of Cannabis
While the FDA is yet to decide and release a rulebook for the usage of cannabis in edible products or its classification, the US Department of Agriculture has released its first comprehensive guide to legal hemp production under the 2018 Farm Bill.
It is an action taken in regard with the planning and production of hemp in the year 2020. The rulemaking will serve as the foundation for the publishing of a proposed rule, comment period, and a final rule.
A farm bill listening session on the subject of hemp production has already been held on March 13, 2019.